NEW YORK - Immunocore idati Lolemba idzagulitsa magawo 3,733,333 mu mgwirizano wandalama wachinsinsi (PIPE) womwe ukuyembekezeka kukweza $ 140 miliyoni.
Pansi pa mgwirizanowu, Immunocore idzagulitsa katundu wake wamba komanso osavota wamba kwa $ 37.50 pagawo lililonse. Ogulitsa omwe ali ndi kampani omwe akugwira nawo ntchito pazachuma akuphatikizapo RTW Investments, Rock Springs Capital ndi General Atlantic.Chigwirizano cha PIPE chikuyembekezeka kutha pa July 20.
Kampaniyo idzagwiritsa ntchito ndalama zomwe zapeza kuti zithandizire anthu omwe akufuna kutsata mapaipi awo a oncology ndi matenda opatsirana, kuphatikiza chitukuko cha mtsogoleri wawo wa oncology, Kimmtrak (tebentafusp-tebn), kuti athandizire HLA-A *02:01 khungu labwino komanso uveal melanoma.
Chaka chino, Kimmtrak wavomerezedwa kuti agwiritsidwe ntchito kwa odwala omwe ali ndi HLA-A * 02: 01 positive unresectable kapena metastatic uveal melanoma ku US, Europe ndi UK, pakati pa mayiko ena.Immunocore ikupitiriza kuphunzira mankhwalawa mu Phase I / II phunziro mu HLA-A * 02: 01-positive cutaneous melanoma.
Immunocore ikupanganso anthu ena anayi a oncology, kuphatikizapo mankhwala awiri owonjezera a T-cell receptor m'mayesero a Phase I / II mu zotupa zolimba zolimba. Mmodzi mwa mankhwalawa akupangidwira odwala HLA-A * 02: 01-positive ndi MAGE-A4-positive, ndipo zolinga zina za HLA-A * 02: 01 ndi PRAME-positive ali ndi zotupa za preclinical zisanachitike.
Zazinsinsi